Understanding bladder cancer — warning signs and blood in urine

Bladder cancer starts in the tissues of the bladder — the hollow organ that stores urine before it leaves the body. It is a condition that often comes to attention because of a very clear warning sign: blood in the urine, also called haematuria. That symptom can be caused by several conditions, many of them not cancer, yet it always deserves prompt medical assessment.

Early assessment matters because it leads to the right investigations, a clear diagnosis, and a treatment plan built around the stage of the disease. In many cases, the path from first symptom to confirmed diagnosis involves cystoscopy and a procedure called TURBT — with surgery forming the backbone of treatment for many patients.

What bladder cancer is and where it starts

Most bladder cancers begin in the inner lining of the bladder. The most common type is urothelial carcinoma, which develops from the cells lining the urinary tract. Some tumours remain close to the surface, while others grow deeper into the bladder wall.

This difference is central to treatment planning. Doctors group bladder cancer into two broad categories based on depth of invasion:

• Non-muscle-invasive bladder cancer (NMIBC) — the tumour has not grown into the bladder muscle. This accounts for around 75% of new diagnoses and is generally more treatable.
• Muscle-invasive bladder cancer (MIBC) — the tumour has grown through the bladder muscle. This requires more intensive treatment and carries a higher risk of spread.

That split has a major effect on what comes next — from local endoscopic treatment to more extensive surgery, radiotherapy, or systemic treatment. Bladder cancer can appear with obvious symptoms, though some cases are found incidentally during investigation of another problem.

Blood in urine and other warning signs

Blood in the urine is the single most consistent warning sign. It may be bright red, pink, or rusty brown. It may happen once and then clear, or come and go over days or weeks. Painless visible haematuria — blood without discomfort — has the highest association with urological malignancy and should never be assumed to be trivial.

Other symptoms that can accompany or precede a diagnosis include:

• Visible blood in the urine — the most important single symptom
• Passing urine more often than usual
• Pain or burning when passing urine
• Waking at night to pass urine (nocturia)
• A strong or sudden urge to pass urine
• Pelvic discomfort

These urinary symptoms can also be caused by infection, bladder stones, or other benign conditions — which is why direct investigation is essential rather than treating symptoms empirically and hoping they clear.

Diagnosis — the pathway from symptom to confirmation

Assessment starts with a review of symptoms, medical history, and risk factors. A clinician will ask about smoking history (the single strongest modifiable risk factor), previous bladder problems, occupational chemical exposure, and family history. Urine tests are part of the initial stage, though they cannot by themselves confirm or rule out bladder cancer.

When bladder cancer is suspected, cystoscopy is the key investigation. NICE guidance specifies that when a urologist considers bladder cancer possible, cystoscopy should be offered to allow direct visual inspection of the bladder lining. This provides information that cannot be matched by imaging or urine tests alone.

What cystoscopy and TURBT mean in practice

Cystoscopy is usually done as an outpatient or day-case procedure. A flexible cystoscope — a thin tube with a camera — is passed through the urethra into the bladder. It sounds daunting, but it is a standard investigation and gives information that cannot be replaced by symptoms or scans.

If an abnormal area is found, TURBT follows. This stands for transurethral resection of bladder tumour. Under anaesthetic, a surgeon passes instruments through the urethra to remove the suspicious area from inside the bladder. The tissue goes to a laboratory pathologist, who determines whether cancer is present, the tumour grade (how aggressive the cells appear), and crucially — how deep the cancer has grown. That depth determines whether the tumour is non-muscle-invasive or muscle-invasive, and therefore what treatment comes next.

TURBT is often both diagnostic and therapeutic — it can remove the visible tumour at the same time as confirming the diagnosis.

Treatment — matched to stage

Treatment depends on stage, grade, general health, and personal priorities. Surgery is the foundation of care for many patients, but what that looks like varies substantially between early and advanced disease.

For non-muscle-invasive disease, the focus is on removing the tumour and reducing the chance of recurrence. Bladder tumours can come back even after successful treatment, which is why regular cystoscopic follow-up is not optional — it is the mechanism by which recurrence is caught early when it is most treatable.

For muscle-invasive localised disease, radical cystectomy — surgical removal of the bladder — remains the most definitive treatment for eligible patients. Urinary diversion is created at the same operation, and the form this takes is discussed carefully beforehand. Bladder-preserving approaches using concurrent chemotherapy and radiotherapy offer an alternative for selected patients who are unsuitable for or choose to avoid surgery.

Follow-up and what to watch for

Follow-up is a major and ongoing part of bladder cancer care. Even when the first treatment is successful, cystoscopic surveillance continues at defined intervals. The frequency typically reduces over time if the bladder remains clear, but it rarely stops entirely for non-muscle-invasive disease.

After TURBT, recovery is usually relatively quick — temporary discomfort, mild bleeding, or urinary irritation are common and settle within days to weeks. Recovery after radical cystectomy or radiotherapy is more demanding and involves longer-term adjustment.

During follow-up, report any new or returning symptoms promptly:

• Blood in the urine — always report, even between scheduled appointments
• Worsening urgency or frequency
• Pain when passing urine
• Pelvic pain or lower back pain
• Unexplained weight loss
• Increasing fatigue